The Singapore-based research network has been designated a World Health Organization (WHO) collaborating centre for clinical trials, according to britcham.org.sg. The appointment was reported on September 1, 2026.
The designation means the network will work in an official capacity with the WHO on matters related to clinical trial research. Collaborating centres are institutions that the WHO partners with to carry out activities in support of its programmes, though the specific scope of this network’s work was not detailed in the report.
The announcement came through the British Chamber of Commerce in Singapore, which highlighted the network’s new status. The exact name of the research network and the duration of the designation were not included in the available information.
This appointment positions the network within a global framework of institutions that contribute to WHO’s technical work. It also underscores Singapore’s growing role in international health research coordination, particularly in the area of clinical trials where the region has been expanding its capabilities.
The WHO collaborating centre status typically involves joint activities such as training, research support, and standard-setting, though no specific projects were mentioned in the report.
What to watch next is whether the network announces specific research priorities or partnerships under this new WHO mandate.
